These observations demonstrate the efficacy of HT-EA in mitigating therapy-responsive induction of β-catenin, MMP9, Ki-67, NKX3.2, PhPT1, GRB10, and MEGF10 in residual PC. This evidence concerns the gene GRB10 and pachyonychia congenita.